Comparing Silverback Therapeutics (NASDAQ:SBTX) and Hepion Pharmaceuticals (NASDAQ:HEPA)

Insider and Institutional Ownership

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Silverback Therapeutics and Hepion Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-3.75
Hepion Pharmaceuticals	N/A	N/A	-$48.93 million	($72.15)	0.00

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares Silverback Therapeutics and Hepion Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Summary

Silverback Therapeutics beats Hepion Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.